Listen
HYDROCORTANCYL (prednisolone), glucocorticoid
RHEUMATOLOGY - Update
Opinions on drugs -
Posted on
Apr 12 2018
Reason for request
Re-assessment of the actual benefit
Low actual benefit and no clinical benefit demonstrated in the treatment of radiculalgia by epidural injection.
- HYDROCORTANCYL has Marketing Authorisation in the treatment of radiculalgia by epidural injection.
- The efficacy data, which provide a low level of evidence, suggest at best a low level of efficacy against pain in the short term.
- No data relating to a possible reduction in recourse to the use of systemic analgesics, recourse to surgery, or to the duration of incapacity have been identified.
- Reinforcement of the precautions for use and contraindications of HYDROCORTANCYL aim to limit the risk of serious neurological complications during epidural injections.
Clinical Benefit
| Low |
- |
Clinical Added Value
| no clinical added value |
- |
English version
Contact Us
Évaluation des médicaments
